The potential for precision medicine is evident. It is one of the most exciting things happening in the healthcare sector. Science and technology advances have made precision medicine no longer an obsession or a dream, its become a reality and will become the mainstream in the future of healthcare, according to our advisory board Co-Chair Dr Zhen Su, Head of Merck KGaAs global oncology franchise. This notion that no one size fits all has long been an interest and passion for many healthcare providers.
This potential is reinforced by Dr Martin Murphy, CEO Roundtable on Cancer: Simply put, it means the future of anybody (with cancer) is embodied in the development of more precise means of diagnoses and then properly treating those with the disease. Its revolutionary and its evolutionary.
While it is most advanced in oncology, precision medicine has wider, exciting applications beyond oncology and late-stage disease, such as rheumatology, and rare and genetic diseases. We are also seeing many innovative initiatives and partnerships develop in this field. For example, Lung-MAP, a large-scale umbrella trial in non-small cell lung cancer, was one of the first to involve partnerships between several groups including the FDA, NCI, advocacy groups and the pharmaceutical industry. At
the same time, we are seeing companies like Flatiron Health using real-world data to learn from patients who are not in clinical trials.There are also important advances in the sharing of data, eg Project Data Sphere, which is an important platform that provides researchers with open-access and analytic tools to use when working with data sets from large clinical trials.
Technology is also moving and being applied at pace: wearable devices such as smart watches, computerised pill bottles and other tools are being evaluated as potentially robust sources of patient-reported data. There are also exciting and much-needed opportunities for patients to play an increasing role in the future, eg patients providing valuable insights into the design of clinical trials will lead to secondary endpoints that are most meaningful for patients themselves rather than for the researchers.
...But what are the barriers?
The challenges around precision medicine are illustrated perfectly by looking at lung cancer as an example: treatments such as chemotherapy and radiation were once fairly standard and broadly applied without much distinction between different patients. However, what was once homogeneous has now become heterogeneous.
Different tumour subtypes have been identified, and exciting advances such as next-generation sequencing (NGS) of tumour DNA can more precisely define key characteristics of an individuals cancer.
Suddenly, one treatment option turns into many, and physicians, particularly those at the community level, struggle to keep up and find it difficult to choose or sequence options.
In addition to new technologies such as NGS, we are seeing the advent of novel trial designs (such as basket trials), and many practising physicians may not understand how to apply or contextualise the resulting data. In addition, the ways that clinical trial data and real-world data complement each other may not be clear, not only to physicians but also to regulatory authorities.
As expressed by Professor George Demetri of the Dana- Farber Cancer Institute and Harvard Medical School: Theres a remarkable need for better communications, both about and around the issues in precision medicine. Because the field is moving so fast, physicians who trained two years ago may not know whats happening today. They have to keep up. Communicating this is almost impossible through standard medical education channels.
Alongside these challenges, there are other barriers to contend with. A lack of public awareness and education may hinder trial recruitment, as patients may not understand the role of trials and may view getting the standard therapy as undesirable.
Additional barriers to participation in clinical trials may also include the lack of a centralised system to match patients to trials and geographic disparities (eg urban versus rural). Beyond the trial setting, perceptions about the efficacy of a drug and logistical barriers such as the lack of technical expertise or centralised technology, and the lack of coverage by insurance companies can limit the use of new therapies in clinical practice.
Finally, patient privacy and ethical considerations become more acute as greater volumes of personal genetic data are generated through clinical evaluations.
Call to action: what can healthcare communication specialists do to help?
Our advisors all felt passionately that we will only overcome the barriers by developing and supporting communication and education efforts to help patients (and expert caregivers, including physicians, nurses and others) to understand precision medicine and the role of clinical trials in healthcare.
The top ten specific needs identified by our advisors include:
Whats next for the McCann Health Global Scientific Council in precision medicine?
We are committed to continuing scientific exchange and public dialogue in this important area of medicine. As outlined by our Global Medical Director and Co-Chair of our Advisory Board, Dan Carucci: Precision medicine is the future of medicine and we as professional health communicators have to stay at the cutting edge so we can help our clients navigate this difficult space.
With the ongoing support of our advisors, we will continue to communicate that precision medicine is integral to healthcare reform. Dr Su is clear: There is an enormous need around how we communicate in a clean, clear and trustworthy manner to enable (physicians) to master new treatments and new technology to better select patients and better provide treatment.
Dr Donna Graham, Medical Oncology Consultant at The Christie NHS Foundation Trust is in agreement with this: Communication between oncologists and their patients is absolutely critical. There are so many complex issues for patients to grasp in terms of treatments that are available and how certain genomic abnormalities may affect their cancer, their prognosis and their outcomes. Communications companies can really help to try to bridge that gap.
In line with our mission to make a meaningful difference in healthcare communications and ultimately to patients, we plan to reconveneour advisors in 2020.
Our aim is to ensure that all our internal team members strengthen their precision medicine expertise, while focusing on the development of external and peer-reviewed communications and tangible tools to benefit the wider medical and patient community. Our call to action will continue as we move to improve the understanding, application and opportunities of precision medicine.
Read the original here:
Staying ahead in the era of precision medicine - PMLiVE
- Clemson professor Trudy Mackay elected to the National Academy of Medicine - Clemson News - October 22nd, 2024
- Research sheds new light on the behavior of KRAS gene in pancreatic and colorectal cancer - News-Medical.Net - October 22nd, 2024
- Pushing the boundaries of rare disease diagnostics with the help of the first Undiagnosed Hackathon - Nature.com - October 22nd, 2024
- Tailored Genetic Medicine: AAV Gene Therapy and mRNA Vaccines Redefine Healthcare's Future - Intelligent Living - October 22nd, 2024
- The Genetic Link to Parkinson's Disease - Hopkins Medicine - August 27th, 2022
- Epic Bio makes gene therapies by editing the epigenome - Labiotech.eu - August 27th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 27th, 2022
- Whole-exome analysis of 177 pediatric patients with undiagnosed diseases | Scientific Reports - Nature.com - August 27th, 2022
- First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN (valoctocogene roxaparvovec), Approved by European Commission (EC) -... - August 27th, 2022
- Arbor Biotechnologies Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in Rare Liver Diseases - BioSpace - August 27th, 2022
- ElevateBio Partners with the California Institute for Regenerative Medicine to Accelerate the Development of Regenerative Medicines - Business Wire - August 27th, 2022
- ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene... - August 27th, 2022
- Genetic variants cause different reactions to psychedelic therapy - The Well : The Well - The Well - August 27th, 2022
- Personalized Medicine for Prostate Cancer: What It Is and How It Works - Healthline - August 27th, 2022
- Four radical new fertility treatments just a few years away from clinics - The Guardian - August 27th, 2022
- Why are Rats Used in Medical Research? - MedicalResearch.com - August 27th, 2022
- The Columns Stepping Stones in STEM Washington and Lee University - The Columns - August 27th, 2022
- Study points to new approach to clearing toxic waste from brain Washington University School of Medicine in St. Louis - Washington University School... - August 27th, 2022
- ALS Gene Therapy SynCav1 Found to Extend Survival in Mouse Model |... - ALS News Today - August 27th, 2022
- A New Kind of Chemo | The UCSB Current - The UCSB Current - August 27th, 2022
- Unraveling the mystery of who gets lung cancer and why - Genetic Literacy Project - June 16th, 2022
- How diet and the microbiome affect colorectal cancer - EurekAlert - June 16th, 2022
- Akouos Presents Nonclinical Data Supporting the Planned Clinical Development of AK-OTOF and Strategies for Regulated Gene Expression in the Inner Ear... - May 20th, 2022
- Money on the Move: SwanBio, Remix, Locus, Mirvie and More - BioSpace - May 20th, 2022
- DiNAQOR Opens DiNAMIQS Subsidiary to Partner with Gene Therapy Companies Bringing New Treatments to Patients - PR Newswire - May 20th, 2022
- Brain tumor growth may be halted with breast cancer drug - Medical News Today - May 20th, 2022
- LogicBio Therapeutics to Present at HC Wainwright Global Investment Conference - PR Newswire - May 20th, 2022
- Genascence Announces Data From Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, Presented at American Society of Gene... - May 20th, 2022
- Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at... - May 20th, 2022
- California, Other States to Cover Rapid WGS of Newborns Under Medicaid, but Questions of Access Loom - GenomeWeb - May 20th, 2022
- Researchers Identify Role of 'Sonic the Hedgehog' Gene in Bone Repair - BioSpace - May 20th, 2022
- Targeting the Uneven Burden of Kidney Disease on Black Americans - The New York Times - May 20th, 2022
- ASC Therapeutics, U Mass Medical School, and the Clinic for Special Children Announce Podium Presentation of Safety and Efficacy in Murine and Bovine... - May 20th, 2022
- UC Davis Looks to Expand Genetic Breast Cancer Risk Education, Outreach for Hispanic Women - Precision Oncology News - May 20th, 2022
- Fly Researchers Find Another Layer to the Code of Life - Duke Today - May 20th, 2022
- CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting - Business... - May 20th, 2022
- Omicron BA.4 and BA.5: What to know about the new variants - Medical News Today - May 20th, 2022
- Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual Meeting -... - May 20th, 2022
- FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2... - May 20th, 2022
- Elucidating the developmental origin of life-sustaining adrenal glands | Penn Today - Penn Today - May 20th, 2022
- 5 questions facing gene therapy in 2022 - BioPharma Dive - January 17th, 2022
- In a First, Man Receives a Heart From a Genetically Altered Pig - The New York Times - January 17th, 2022
- Antibodies, Easy Single-Cell, Genomics for All: Notes from the JP Morgan Healthcare Conference - Bio-IT World - January 17th, 2022
- Using genetics to conserve wildlife - Pursuit - January 17th, 2022
- Genetics of sudden unexplained death in children - National Institutes of Health - January 17th, 2022
- Amicus Therapeutics Reports Preliminary 2021 Revenue and Provides 2022 Strategic Outlook and Revenue Guidance - Yahoo Finance - January 17th, 2022
- Maze Therapeutics Announces $190 Million Financing to Support the Advancement of Nine Precision Medicine Programs and Compass Platform for Genetically... - January 17th, 2022
- How The mRNA Vaccines Were Made: Halting Progress and Happy Accidents - The New York Times - January 17th, 2022
- Press Registration Is Now Open for the 2022 ACMG Annual Clinical Genetics Meeting - PRNewswire - January 17th, 2022
- A Novel Mutation in the TRPM4 Gene | RRCC - Dove Medical Press - January 17th, 2022
- Biomarkers and Candidate Therapeutic Drugs in Heart Failure | IJGM - Dove Medical Press - January 17th, 2022
- Genetic counseling program helps patients take control of their health - Medical University of South Carolina - June 24th, 2021
- One-year-old baby in UAE receives imported genetic medicine to treat rare disease - Gulf News - June 24th, 2021
- Black and non-Hispanic White Women Found to Have No Differences in Genetic Risk for Breast Cancer - Cancer Network - June 24th, 2021
- What's in your genes | The Crusader Newspaper Group - The Chicago Cusader - June 24th, 2021
- Immusoft Announces Formation of Scientific Advisory Board - Business Wire - June 24th, 2021
- Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress - Business... - June 24th, 2021
- Pacific Biosciences and Rady Children's Institute for Genomic Medicine Announce its First Research Collaboration for Whole - GlobeNewswire - June 24th, 2021
- Despite the challenges of COVID-19, Yale-PCCSM section members continued their work on scientific papers - Yale School of Medicine - June 24th, 2021
- Veritas Intercontinental: Genetics makes it possible to identify cardiovascular genetic risk and prevent cardiac accidents such as those that have... - June 24th, 2021
- New Research Uncovers How Cancers with Common Gene Mutation Develop Resistance to Targeted Drugs - Newswise - June 24th, 2021
- Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 - PRNewswire - February 14th, 2021
- How will WNY fare in the race between vaccines and coronavirus variants? - Buffalo News - February 14th, 2021
- Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences - GlobeNewswire - February 14th, 2021
- ASCO GU 2021: The Landscape of Genetic Alterations Using ctDNA-based Comprehensive Genomic Profiling in Pat... - UroToday - February 14th, 2021
- The Human Genome and the Making of a Skeptical Biologist - Scientific American - February 14th, 2021
- Breast Cancer Gene Mutations Found in 30% of All Women - Medscape - February 1st, 2021
- Mysterious untreatable fevers once devastated whole families. This doctor discovered what caused them - CNN - February 1st, 2021
- CCMB team identifies variants of genes that metabolise drugs - BusinessLine - February 1st, 2021
- NeuBase Therapeutics Announces Acquisition of Gene Modulating Technology from Vera Therapeutics - GlobeNewswire - February 1st, 2021
- Copy number variations linked to autism have diverse but overlapping effects - Spectrum - February 1st, 2021
- Genomes, Maps, And How They Affect You - IFLScience - February 1st, 2021
- SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected - PRNewswire - February 1st, 2021
- Are Phages Overlooked Mediators of Health and Disease? - The Scientist - February 1st, 2021
- When Your Chance for a Covid Shot Comes, Dont Worry About the Numbers - Kaiser Health News - February 1st, 2021
- Global CRISPR Gene Editing Market: Focus on Products, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and... - February 1st, 2021
- The First Targeted Therapy For Lung Cancer Patients With The KRAS Gene MutationExtraordinary Results With Sotorasib - SurvivorNet - February 1st, 2021
- Genetic Testing: MedlinePlus - January 29th, 2021
- 21 Common Genetic Disorders: Types, Symptoms, Causes ... - January 29th, 2021
- Genetic Counseling Online Course - School of Medicine ... - January 29th, 2021